Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Unprofitable companies face an uphill battle, but not all are created equal. Luckily for you, StockStory is here to separate the promising ones from the weak. That said, here are three unprofitable companiesthat don’t make the cut and some better opportunities instead.

Kura Sushi (KRUS)

Trailing 12-Month GAAP Operating Margin: -2.4%

Known for its conveyor belt that transports dishes to diners, Kura Sushi (NASDAQ: KRUS) is a chain of sushi restaurants serving traditional Japanese fare with a touch of modernity and technology.

Why Does KRUS Give Us Pause?

1. Disappointing same-store sales over the past two years show customers aren’t responding well to its menu offerings and dining experience
2. Cash burn makes us question whether it can achieve sustainable long-term growth
3. Short cash runway increases the probability of a capital raise that dilutes existing shareholders

Kura Sushi’s stock price of $70.37 implies a valuation ratio of 41.9x forward EV-to-EBITDA. Read our free research report to see why you should think twice about including KRUS in your portfolio.

Enovis (ENOV)

Trailing 12-Month GAAP Operating Margin: -50%

With a focus on helping patients regain or maintain their natural motion, Enovis (NYSE: ENOV) develops and manufactures medical devices for orthopedic care, from injury prevention and pain management to joint replacement and rehabilitation.

Why Should You Sell ENOV?

1. Annual sales declines of 6% for the past five years show its products and services struggled to connect with the market during this cycle
2. Push for growth has led to negative returns on capital, signaling value destruction, and its falling returns suggest its earlier profit pools are drying up
3. Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned

At $25.48 per share, Enovis trades at 7.1x forward P/E. Dive into our free research report to see why there are better opportunities than ENOV.

PacBio (PACB)

Trailing 12-Month GAAP Operating Margin: -346%

Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ: PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness.

Why Are We Cautious About PACB?

1. Sales tumbled by 10.7% annually over the last two years, showing market trends are working against its favor during this cycle
2. Cash-burning tendencies make us wonder if it can sustainably generate shareholder value
3. Negative earnings profile makes it challenging to secure favorable financing terms from lenders

PacBio is trading at $1.69 per share, or 3.1x forward price-to-sales. If you’re considering PACB for your portfolio, see our FREE research report to learn more.

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.